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Abstract 
Background: Adhesion complex molecules have been found to be abnormally 
expressed in gastric cancer. Several mechanisms are known to be responsible for these 
alterations, though they do not explain all cases. MicroRNAs regulate protein 
expression post-transcriptionally, and have been described to be associated with 
several human malignancies. Our goals were to investigate the expression levels of 
four microRNAs in gastric cancer and to find possible relationships between these 
microRNAs and adhesion complex molecules’ mRNAs. 
Methodology/Principal Findings: Bioinformatics analysis predicted which 
microRNAs could target 3’ untranslated regions of adhesion complex molecules’ 
mRNAs. We compared this information with a microarray analysis that we had 
previously performed. Quantitative real-time PCR was used to measure the expression 
of miR-9, miR-143, miR-579, miR-942 and adhesion complex molecules’ mRNAs in 
nine gastric cancer cell lines and four tumours. We found that miR-9 was significantly 
down-regulated in six gastric cancer cell lines and three tumours, in agreement with 
previous studies. We also found that miR-143 was significantly under-expressed in all 
cell lines and one tumour, as reported by others. Here we describe, for the first time, 
that miR-579 is up-regulated in gastric cancer cell lines. However, two tumours 
revealed significant down-regulation of miR-579. In a similar way, miR-942 was 
over-expressed in cell lines and three tumours, while another one showed under-
expression of miR-942. We did not find any significant correlation between studied 
microRNAs and mRNAs. 
Conclusions/Significance: We found that miR-9, miR-143, miR-579 and miR-942 
are differentially expressed in gastric cancer cell lines and tumours. Although our 
findings point to a potential targeting of these microRNAs over 3’ untranslated 
regions of adhesion complex molecules’ mRNAs, it was not possible to evidence a 
causal relationship in this preliminary study. Further studies, such as luciferase 
reporter assays, should be performed to investigate this. 
 
Key-words: microRNAs; miR-9; miR-143; miR-579; miR-942; adhesion complex; 
gastric cancer. 
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Introduction 
Gastric cancer (GC) is responsible for nearly 10% of all cancer-related deaths (as 
estimated by GLOBOCAN 2008 [1]) and, despite every effort, the overall outcome 
remains poor. Several genetic and epigenetic alterations have been implicated in the 
pathogenesis of the different histologic types of gastric cancer [2]. 
E-cadherin, α-catenin, β-catenin and p120 are the main components of the adhesion 
complex. The extracellular domain of E-cadherin is responsible for cell-cell adhesion 
of epithelial cells, while its cytoplasmic tail interacts with β-catenin [3,4]. α-catenin 
binds β-catenin to the actin cytoskeleton and p120, which binds to the juxtamembrane 
domain of classical cadherins, appears to be responsible for the lateral clustering of 
cadherin molecules [3,4]. Disruption of this complex can lead cells to lose polarity, 
gain invasive properties and increased signal transduction [3,4]. 
Several studies reported abnormal expression of E-cadherin, β-catenin, α-catenin and 
p120 in gastric cancer [5-7]. E-cadherin (encoded by CDH1 gene) is one of the best 
characterized molecules. In sporadic diffuse-type gastric cancer E-cadherin can be 
inactivated by somatic mutations in CDH1 gene, promoter methylation and loss of 
heterozygosity (LOH); while in hereditary diffuse gastric cancer (HDGC) E-cadherin 
is silenced by germline alterations in the CDH1 gene (mutations and deletions) 
followed by a somatic second-hit inactivation mechanism in the tumour [8-11]. In 
sporadic intestinal-type gastric cancer no mutations of CDH1 gene have been found 
[2,12], but rather promoter methylation and LOH [13]. 
As for the β-catenin gene (CTNNB1), it has been found to be mutated in intestinal-
type GC and amplified in mixed-type GC [14]. Until now, no mutations in α-catenin 
(CTNNA1) or p120 (CTNND1) genes have been described [3]. Nevertheless, the 
above mentioned mechanisms are insufficient to explain the widely observed 
abnormal expression of these adhesion complex molecules in gastric cancer. Thus, we 
aimed to find possible regulators of adhesion complex molecules proteins’ expression 
in gastric cancer. 
MicroRNAs (miRNAs or miRs), small (18-22 nucleotides) non-coding RNAs, are key 
gene regulators expressed in several organisms, including Homo sapiens. In 
mammals, miRNAs repress target-gene expression post-transcriptionally binding by 
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imperfect complementarity to the 3’ untranslated regions (3’UTRs) of their mRNA 
targets [15-17]. There are four major mechanisms of miRNA-mediated repression: 
deadenylation, proteolysis, initiation block or elongation block [18,19]. MicroRNAs 
can act both as oncogenes or tumour suppressor genes, according to their target’s 
function. In the last few years several miRNAs have been associated with different 
human cancers, including gastric cancer [15-17]. 
Our group has previously performed a microarray analysis of 37 gastric cancer 
tumours, which revealed several differentially expressed microRNAs [20]. Of those, 
we have chosen to quantify miR-9, miR-143, miR-579 and miR-942 because 
bioinformatics analysis revealed that these microRNAs could potentially target 
adhesion complex molecules. 
MiR-9 has been extensively studied and appears to have different levels of expression 
and functions according to the type and stage of cancer. For example, miR-9 was 
shown to be up-regulated in metastasis of brain [21], breast [22] and colorectal [23] 
tumours. These findings could be explained because miR-9 was shown to target the 
3’UTRs of CDH1 and CTNNA1 genes, negatively regulating the expression of E-
cadherin and α-catenin, therefore promoting cell motility and metastasis. In addition, 
it has been claimed that down-regulation of E-cadherin allows activation of β-catenin 
signalling pathway, which up-regulates the expression of vascular endothelial growth 
factor [22] – a promoter of tumour angiogenesis. In contrast, when evaluating miR-9 
expression in ovarian cancer [24], gastric cancer [25] and melanoma [26] it was found 
that down-regulation of miR-9 lead to nuclear factor-kappa B1 (NF-κB1) pathway de-
repression, consequently increasing E-cadherin expression. How miR-9 accomplishes 
different roles in different types of cancer is still not understood. 
MiR-143 is believed to have tumour-suppressor functions as it was found to be 
systematically down-regulated in various human cancers, namely osteosarcoma, 
oesophageal squamous cell, gastric and colorectal carcinomas [27-30]. According to 
Ng, E. et al. [31], in colorectal cancer this microRNA exerts its tumour-suppressive 
role by targeting the DNA methyltransferase 3A (DNMT3A) gene. Additionally, it was 
described that overexpression of miR-143 increases apoptosis and protects cells from 
DNA damage-induced killing by targeting B-cell lymphoma 2 (Bcl-2) and fragile 
histidine triad (FHIT) [27,32,33]. 
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On the other hand, miR-579 and miR-942 have not been found to be differentially 
expressed in any type of human cancer or to have a possible biological role in cancer. 
Our aim in this preliminary study was to quantify mature miR-9, miR-143, miR-579, 
miR-942 and the four adhesion complex molecules in GC and to find possible 
relationships between microRNAs and adhesion complex molecules’ mRNAs, which 
could point to a potential targeting of microRNAs over 3’UTRs of adhesion complex 
mRNAs. We analysed all four microRNAs and adhesion complex molecules’ mRNAs 
in a panel of nine gastric cancer cell lines and four primary gastric tumours and 
compared them to samples of normal stomach. In the present study we showed that all 
four miRs analysed revealed different expression levels (down- or up-regulation) in 
gastric cancer cell lines and/or tumours. Although our findings point to a potential 
targeting of these microRNAs over 3’UTRs of adhesion complex molecules’ mRNAs, 
it was not possible to evidence a causal relationship in this preliminary study. 
 
Material and methods 
MiRNA selection 
Previous results of a microRNA microarray experiment performed in primary gastric 
cancers generated a list of differentially expressed candidate miRNAs [20]. MiRWalk 
[34] was used to predict which of these miRNAs could target 3’UTRs of CDH1, 
CTNNA1, CTNNB1 and CTNND1 genes. All eight prediction programs were chosen. 
MiRNAs that were predicted to target the above mentioned genes by at least four 
programs were included for further study. BioVenn [35] was used to draw Venn 
diagrams to highlight which miRNAs were common to at least two of the genes. 
Using this approach we selected a list of four miRNAs that could target at least one of 
the adhesion complex genes. 
Biological material 
Cell lines 
We studied nine human gastric carcinoma cell lines: AGS; GP202 and IPA220 
(previously established in our laboratory [36]); Kato-III; MKN28; MKN45; NCI-N87; 
SNU1 and SNU638 (from IPATIMUP’s cell line bank). 
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AGS is a cell line derived from fragments of a gastric adenocarcinoma resected from 
a patient who had received no prior therapy. Kato-III is derived from metastatic 
pleural effusion secondary to a poorly-differentiated gastric adenocarcinoma. GP202 
and IPA220 are cell lines derived from a primary diffuse gastric carcinoma. MKN28 
is a cell line derived from lymph node metastasis of a moderately differentiated 
tubular adenocarcinoma, while MKN45 is derived from liver metastasis of a poorly 
differentiated gastric adenocarcinoma. NCI-N87 is derived from liver metastasis of a 
gastric carcinoma from a patient who had received no prior therapy. SNU1 and 
SNU638 were developed from a poorly differentiated primary carcinoma of the 
stomach, also from a patient who had received no prior therapy. 
Commercial pool of normal stomach 
A commercial pool of normal stomach (Ambion®; AM7996), which contains human 
stomach total RNA, was used as a reference sample for gastric cancer cell lines. 
Tumours 
Paraffin embedded tumour specimens (n = 4 GC) were collected from the Pathology 
Departments, Leeds University Hospitals and VUmc in Amsterdam. Informed consent 
was obtained from all patients and the study was approved by the appropriate hospital 
ethics committees. Tumours were labeled from T1 to T4 by no special order and all 
displayed abnormal protein expression of adhesion-complex molecules (data not 
shown). 
Stomach pool of normal samples 
A stomach pool of normal samples was previously established in our laboratory. RNA 
was extracted from ten normal stomach biopsies and mixed together to serve as a 
reference sample for tumours. 
RNA extraction 
Total RNA, including small RNAs, was extracted from cell lines with the miRvana™ 
miRNA Isolation Kit (Ambion®, Austin, TX), according to the manufacturer’s 
instructions. In brief, samples were lysed followed by an acid-phenol chloroform 
extraction. Total RNA was collected and small RNAs were purified by precipitation 
with ethanol. Small RNAs were immobilized on glass-fibre filters, washed and eluted 
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with 30 to 60 µL of nuclease-free water. RNA concentration and purity were 
evaluated by measuring A260 and A280 absorbance in a NanoDrop® Spectrophotometer 
ND-1000 (Alphagene®). Ratios of absorbance (A260:A280) between 1.8 and 2.0 were 
considered optimal. RNA was stored at -20ºC. 
Reverse Transcription of miRNAs 
Single-stranded cDNA was generated using TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, USA). In brief, each reaction 
consisted on 10 ng of small RNA, 0.15 µL of dNTP Mix with dTTP (100 mM total), 
0.19 µL of RNase Inhibitor (20 U/µL), 1.5 µL of 10x RT Buffer, 1 µL of 
Multiscribe™ RT enzyme (50 U/µL), 3 µL of 5X RT Primer and nuclease-free water 
for a final volume of 15 µL. RT Primers (5X) used were: hsa-miR-9 (RT 583; Applied 
Biosystems), hsa-miR-143 (RT 2249; Applied Biosystems), hsa-miR-579 (RT 2398; 
Applied Biosystems), hsa-miR-942 (RT 2187; Applied Biosystems) and RNU48 (RT 
1006; Applied Biosystems). The reaction was performed at 16ºC for 30 minutes, 42ºC 
for 30 minutes followed by 85ºC for 5 minutes. The products were stored at -20ºC. 
Quantitative Real-time PCR of miRNAs 
The expression of miRNAs was quantified by quantitative real-time PCR (qRT-PCR). 
RT reactions were carried out in final volumes of 10 µL using a 7500 Fast Real-Time 
PCR System (Applied Biosystems). For cell lines, each RT reaction consisted of 2.66 
µL cDNA, 5 µL of TaqMan® 2X Universal PCR Master Mix No AmpErase® UNG 
(Applied Biosystems, New Jersey, USA), 1.84 µL of nuclease-free water and 0.5 µL 
of 20X Real-Time probe. For tumours the conditions used were: 3 µL cDNA, 5 µL of 
TaqMan® 2X Universal PCR Master Mix No AmpErase® UNG (Applied Biosystems, 
New Jersey, USA), 1.5 µL of nuclease-free water and 0.5 µL of 20X Real-Time 
probe. Real-Time probes (20X) used were: hsa-miR-9 (TM 583; Applied 
Biosystems), hsa-miR-143 (TM 2249; Applied Biosystems), hsa-miR-579 (TM 2398; 
Applied Biosystems), hsa-miR-942 (TM 2187; Applied Biosystems) and RNU48 (TM 
1006; Applied Biosystems). The reactions were loaded into a MicroAmp® Fast 
Optical 96-Well Reaction Plate 0.1 mL (Applied Biosystems, Foster City, USA). PCR 
was performed under the following conditions: 95ºC for 10 minutes, followed by 45 
cycles of 95 ºC for 15 seconds and 60ºC for 60 seconds. The assay was run in 
triplicate to assess technical variability. 
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The degree of expression was calculated by the ∆∆Ct comparative method [37]. In 
gastric cancer cell lines and tumours, RNU48 was assumed as endogenous control. 
Commercial stomach and stomach pool of normal samples were used as 
reference/calibrator samples for cell lines and tumours, respectively. ∆Ct refers to the 
difference between mean Ct value of target gene and mean Ct value of endogenous 
control (RNU48). ∆∆Ct refers to the difference between ∆Ct Sample and ∆Ct 
Calibrator. 2-∆Ct refers to gene expression normalized to endogenous control, while 2-
∆∆Ct
 refers to fold change of gene expression (normalized to reference sample). 
Reverse transcription of mRNAs 
In cell lines, total RNA (1µg) was reverse transcribed using: 0.75 µL Superscript® II 
Reverse Transcriptase (200 U/µL; Invitrogen), 4 µL 5X First Strand Buffer 
(Invitrogen), 2 µL DTT (0.1M; Invitrogen), 1 µL dNTPs, 0.2 µL rRNasin® RNase 
Inhibitor (40 U/µL; Promega, Madison WI, USA), 0.75 µL nuclease-free water and 1 
µL random primers (0.1 µg/µL). The amplification was performed by denaturing at 
70ºC for 10 minutes; annealing at 4ºC, 2 minutes; and extension at 37ºC for 60 
minutes. The products were stored at -20ºC. In tumours, cDNA was reverse 
transcribed by the same conditions, except that total RNA used was 400 ng. 
Quantitative Real-time PCR of mRNAs 
RT reactions were performed as described previously, except that PCR was performed 
under the following conditions: 50ºC for 20 seconds, 95ºC for 10 minutes, followed 
by 45 cycles of 95 ºC for 15 seconds and 60ºC for 60 seconds. The assay was run in 
triplicate to assess technical variability. Real-Time probes (20X) used were: CDH1 
6/7 (Hs01023895_m1 CDH1; Applied Biosystems), CDH1 1/2 (Hs01013959_m1 
CDH1; Applied Biosystems), CTNNA1 (Hs00944794_m1 CTNNA1; Applied 
Biosystems), CTNNB1 (Hs00355045_m1 CTNNB1; Applied Biosystems), CTNND1 
(Hs00931670_m1 CTNND1; Applied Biosystems), GADPH (Hu GAPD; Applied 
Biosystems) and 18S (Hs99999901_s1; Applied Biosystems). 
In gastric cancer cell lines, degree of expression was calculated by the ∆∆Ct 
comparative method [37], assuming GAPDH as endogenous control and commercial 
stomach as reference/calibrator sample. In tumours, 18S was used as endogenous 
control and a pool of normal stomach samples as reference sample. 2-∆Ct refers to gene 
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expression normalized to endogenous control, while 2-∆∆Ct refers to fold change of 
gene expression (normalized to reference sample). 
Statistical analysis 
Students’ t-test (unequal variances) was used to compare expression levels of 
microRNA and mRNA in gastric cancer cell lines and tumours to commercial pool of 
normal stomach and stomach pool of normal samples, respectively. Spearman’s 
correlation was used to evaluate possible correlations between microRNA and 
mRNA. Gastric cancer cell lines’ data are expressed as mean ± standard error mean 
(S.E.M.) from two independent experiments performed in triplicates. Tumours’ data 
are expressed as mean ± standard error (S.E.) from one independent experiment 
performed in triplicate. Statistical calculations were performed using Microsoft Excel 
2010® and GraphPad® Prism software v5.0.3. Figures were drawn using GraphPad® 
Prism software v5.0.3. All p-values are two-sided and considered to be statistically 
significant if < 0.05. 
 
Results 
MiRNAs target genes prediction 
Our group has previously performed a microarray analysis of 37 gastric cancer 
tumours [20] which revealed several differentially expressed microRNAs. 
Bioinformatics analysis predicted several of these microRNAs to target 3’UTRs of 
CDH1, CTNNA1, CTNNB1 and CTNND1 genes. Then, we cross-matched microarray 
analysis information with bioinformatics analysis information and we chose to 
quantify miR-9, miR-143, miR-579 and miR-942. The predicted targets for each of 
these microRNAs are shown in Table 1. 
Adhesion complex molecules’ mRNAs expression in gastric cancer cell 
lines and tumours 
Using quantitative real-time PCR (qRT-PCR), we investigated the expression levels 
of adhesion complex molecules’ mRNAs in gastric cancer cell lines and tumours in 
comparison with their normal counterparts (commercial pool of normal stomach – 
Stm; and stomach pool of normal samples – pool Stm).  
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Although not statistically significant, we found that CDH1 mRNA was under-
expressed in all gastric cancer cell lines, except MKN28 (Figure 1A). 
Although not statistically significant, CTNNA1 mRNA levels appear to be down-
regulated in all gastric cancer cell lines, except in Kato-III and MKN28 where they 
are up-regulated (statistically significant in MKN28), and in AGS where they appear 
not to be different (Figure 1B). 
CTNNB1 mRNA was found to be over-expressed in Kato-III and MKN28 (not 
statistically significant), while it was under-expressed in SNU1, GP202, SNU638, 
MKN45 and NCI-N87 (p < 0.05). On the other hand, AGS and IPA220 cell lines do 
not appear to have different CTNNB1 mRNA levels when compared to commercial 
stomach (Figure 1C). 
CTNND1 mRNA revealed higher levels of expression in Kato-III and MKN28 cell 
lines, while it was down-regulated in all other gastric cancer cell lines (Figure 1D).  
In contrast, when analysing four tumour samples, we found that all adhesion complex 
molecules’ mRNAs were consistently over-expressed (Figure 1E). 
Overall, this analysis presents two distinct scenarios: in gastric cancer cell lines, 
adhesion complex molecules’ mRNA levels are generally down-regulated in 
comparison to the normal counterpart; while in primary tumours, the opposite is 
observed. 
MicroRNAs expression in gastric cancer cell lines and tumours 
We examined the expression of miR-9, miR-143, miR-579 and miR-942 in cell lines 
and tumours in comparison to normal samples by qRT-PCR. 
MiR-9 
We found that miR-9 was significantly down-regulated in six gastric cancer cell lines 
(Figure 2A). MKN28 also expressed low levels of miR-9 but the difference was not 
statistically significant. On the other hand, miR-9 was up-regulated in MKN45 and 
NCI-N87 cell lines (Figure 2A). Overall, gastric cancer cell lines appear to have lower 
expression of miR-9 than normal cells, although the difference is not statistically 
significant (Figure 2B; p = 0.115). We then examined the expression of miR-9 in four 
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tumour samples and a pool of normal gastric samples. We found that miR-9 was 
consistently down-regulated in all four tumour samples (Figure 2C and 2D). 
Altogether these data support the view that miR-9 is down-regulated in gastric cancer. 
MiR-143 
MiR-143 was found to be significantly and consistently down-regulated both 
individually (Figure 3A) and collectively (Figure 3B) in gastric cancer cell lines. In 
tumour T1, miR-143 was found to be down-regulated, as happened in cell lines 
(Figure 3C). However, the findings were not universal since tumours T2 and T3 
expressed higher levels of miR-143 than normal stomach, and tumour T4 displayed 
levels of expression equivalent to those of normal samples (Figure 3C). Overall 
comparison found no difference in miR-143 levels between tumours and normal 
gastric samples (Figure 3D). 
MiR-579 
MiR-579 was found to be consistently up-regulated in all gastric cancer cell lines, 
even though statistical significance was only achieved in GP202 (Figure 4A). The 
overall comparison of gastric cancer cell lines with the normal counterpart was 
statistically significant (Figure 4B). In agreement with these findings, one tumour (T2; 
Figure 4C) appeared to show over-expression of miR-579. However, tumours T3 and 
T4 revealed significant lower expression levels of miR-579 (Figure 4C). Overall 
comparison favoured down-regulation of miR-579 in tumours (Figure 4D). 
MiR-942 
Similarly, miR-942 seemed to be up-regulated in all gastric cancer cell lines (Figure 
5A), although statistical significance was only achieved in the overall comparison 
(Figure 5B). Concordantly, three tumours (T1, T2 and T4; Figure 5C) showed over-
expression of miR-942. However, T3 expressed significantly lower levels of miR-942 
than normal samples (Figure 5C). Overall, miR-942 expression appears to be up-
regulated in tumours, even though statistical significance was not achieved (p = 0.063; 
Figure 5D). 
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Expression relationship between predicted microRNA/mRNA pairs in 
gastric cancer cell lines and tumours 
In an attempt to find possible relationships between microRNAs and adhesion 
complex molecules’ mRNAs we compared predicted (Table 1) and non-predicted 
microRNA/mRNA pairs, using as a reference the relationship in normal stomach. 
Furthermore, since one of the mechanisms of microRNA-mediated gene regulation is 
mRNA deadenylation and degradation [18,19], we applied Spearman’s correlation to 
these pairs to understand if microRNAs can potentially target 3’UTRs of adhesion 
complex mRNAs. 
MiR-9 
MiR-9 was predicted to bind the 3’UTRs of CDH1 and CTNNA1 mRNAs. 
Nevertheless, we did not find a relationship between the expression of miR-9 and the 
expression of these mRNAs in gastric cancer cell lines (Figure 6A) – as the 
expression of miR-9 was lower than the two molecules mRNAs’ expression in normal 
samples and cell lines. However, in SNU1 and MKN45 cell lines the relationships 
between miR-9 and CDH1 mRNA and between miR-9 and adhesion complex 
molecules’ mRNAs are inverted, respectively. Tumours T2, T3 and T4 presented a 
different scenario, as the expression of miR-9 was lower than that of CDH1 and 
CTNNA1 mRNAs, in contrast to what happened in normal stomach where miR-9 is 
over-expressed in relation to these two molecules’ mRNAs (Figure 7A). This same 
event was observed for the non-predicted mRNAs of CTNNB1, but not for CTNND1 
(Figures 6A and 7A). 
In gastric cancer cell lines, Spearman’s correlation did not find any significant 
correlation between predicted or non-predicted mRNAs and miR-9 (Figure 8A). On 
the other hand, although not statistically significant, we found a possible inverse 
correlation between miR-9 and CTNNB1 in tumours (Figure 9A; Spearman r = - 0.9; 
p = 0.0833), in agreement with what was described above. There were no significant 
correlations between miR-9 and other mRNAs in tumours. 
MiR-143 
MiR-143 was predicted to target the 3’UTRs of CDH1 and CTNND1 mRNAs. In 
gastric cancer cell lines (except SNU1), we noticed that the relationship between these 
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mRNAs and miR-143 was inverted (Figure 6B). This was also observed for the non-
predicted mRNAs (Figure 6B). In contrast, all tumours maintained the same 
relationship with all adhesion complex mRNAs as their normal counterpart (Figure 
7B). No significant Spearman’s correlation was found in either cell lines or tumours 
(Figures 8B and 9B).  
MiR-579 
MiR-579 was predicted to bind the 3’UTRs of CTNNA1, CTNNB1 and CTNND1 
mRNAs. However, we did not find any relationship between miR-579 and these 
mRNAs in gastric cancer cell lines, since the relationship that is observed in normal 
stomach was maintained (Figure 6C). In contrast, we found that the relationship 
shifted in tumours T3 and T4, as miR-579 is down-regulated and CTNNA1, CTNNB1 
and CTNND1 mRNAs are up-regulated, while in T1 and T2 the relationship appears 
to be the same as in the normal counterpart (Figure 7C). The non-predicted CDH1 
mRNA relationship with miR-579 was inverted in SNU1, AGS, T3 and T4, but not in 
the remaining cell lines and tumours (Figures 6C and 7C). 
No significant correlation was found in cell lines or tumours for both predicted and 
non-predicted miR-579/mRNA pairs (Figure 8C and 9C). 
MiR-942 
MiR-942 was predicted to target the 3’UTRs of CTNNA1 and CTNND1 mRNAs, but 
we were not able to find any relationship between them in gastric cancer cell lines 
(Figure 6D). Similarly, in all tumours no relationship was found between miR-942 
and CTNND1 (Figure 7D). On the other hand, miR-942 and CTNNA1 relationship 
was inverted in T3 (Figure 7D). Regarding non-predicted CDH1 and CTNNB1 
mRNAs, in gastric cancer cell lines, SNU1 and AGS showed an inverted relationship 
between this microRNA and CDH1 mRNA, but no relation was noted concerning 
CTNNB1 (Figure 6D). In tumours, T3 and T4 showed inversion of the relationship 
between miR-942 and CDH1 mRNA, while only T3 showed an inverted relationship 
with CTNNB1 (Figure 7D). 
No significant correlation was found in either cell lines or tumours for both predicted 
and non-predicted miR-942/mRNA pairs (Figure 8D and 9D). 
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Globally, our findings suggest some possible interactions between the four selected 
miRNAs (miR-9, miR-143, miR-579 and miR-942) and the expression of adhesion 
complex molecules’ mRNAs, nonetheless this analysis was inconclusive. 
Discussion 
In our study, we found that CDH1 mRNA was under-expressed in all gastric cancer 
cell lines except MKN28. Interestingly, although not always statistically significant, 
MKN28 appears to reveal high levels of the other three adhesion complex molecules’ 
mRNAs (namely CTNNA1, CTNNB1 and CTNND1). These findings are not 
surprising, since MKN28 represents a moderately differentiated tubular 
adenocarcinoma. In contrast, the other gastric cancer cell lines which represent more 
undifferentiated tumours, have revealed under-expression of at least one adhesion 
complex molecule’s mRNA, possibly indicating disruption of the adhesion complex. 
We also found that CDH1 mRNA was down-regulated in SNU1 cell line, in 
agreement with CDH1 promoter methylation (Carvalho et al, unpublished data); and 
that CTNNB1 mRNA was up-regulated in Kato-III cell line, in agreement with the β-
catenin amplification that has already been described [38]. 
In the present study, we chose tumours displaying abnormal protein expression of 
adhesion-complex molecules. Despite this, we found that all of them revealed up-
regulation of all adhesion complex molecules’ mRNAs. This may reveal an 
unanticipated effect over translation of these adhesion complex molecules. 
MiR-9 has been shown be up-regulated in primary breast tumour samples from 
metastasis-positive patients [22]. It was demonstrated that miR-9 suppresses E-
cadherin expression by directly targeting 3’UTR of CDH1 mRNA in SUM149 breast 
cancer cells, thereby promoting cell motility and invasiveness [22]. In contrast, our 
findings indicated that miR-9 appears to be under-expressed in gastric cancer, which 
was also reported by Luo H. et al. [39], Wan H.Y. et al. [25] and Tsai K.T. et al. [40]. 
One possible explanation for miR-9 down-regulation in gastric cancer was advanced 
by Tsai K.T. et. al. [40], who reported that miR-9 is silenced by DNA 
hypermethylation in gastric cancer. The consequences of miR-9 under-expression in 
gastric cancer are still under study. In one study, it was proposed that RAB34 (a 
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member of RAS oncogene family) could be activated, triggering Ras-MAPK 
signalling pathway as a consequence of miR-9 down-regulation [39]. Others found 
that NF-κB1 is a direct target of miR-9, but they did not elucidate its exact role [25]. 
Later, it was shown that under-expression of miR-9 decreases the repression of NF-
κB1 in melanoma, thereby up-regulating Snail1 which is a potent repressor of E-
cadherin [26]. Still, it should be investigated if these findings apply to gastric cancer 
and whether they could explain our results. In the present study, although not 
statistically significant, MKN45 cell line expressed higher levels of miR-9 (as 
reported by others [41]), while NCI-N87 cell line has slightly higher levels of miR-9 
when compared to normal stomach. As these two gastric cancer cell lines retain E-
cadherin expression at the membrane (Carvalho et al, unpublished data), it would be 
interesting to study which other effects may miR-9 up-regulation have in this context. 
MiR-143 appears to have a tumour suppressor role in gastrointestinal tumours since it 
has been shown to be systematically down-regulated in this type of tumours [28-32]. 
Here, we confirmed that miR-143 is consistently down-regulated in gastric cancer cell 
lines. However, we found that two tumours revealed up-regulation of miR-143, while 
just one of the tumours analysed (T1) revealed under-expression. Until now, up-
regulation of miR-143 has only been reported in hepatocarcinoma metastasis [42]. 
Some mechanisms have been elucidated on how down-regulation of miR-143 could 
influence gastrointestinal carcinogenesis. In colorectal cancer it was found that miR-
143 directly targets K-Ras [43]. Consequently, when miR-143 is under-expressed, 
RAS/RAF/MEK/ERK signalling pathway is activated, leading to increased cell 
proliferation, suppression of cell apoptosis and deregulation of cell cycle [43]. It was 
also described that overexpression of miR-143 increases apoptosis and protects cells 
from DNA damage-induced killing by targeting Bcl-2 and FHIT [27,32,33]. Others 
found that in colorectal cancer, miR-143 targets DNMT3A [31]. Therefore, down-
regulation of miR-143 results in up-regulation of DNMT3A which can silence tumour 
suppressor genes by hypermethylation [31]. Despite the fact that DNMT3A was 
shown to be up-regulated in gastric cancer tissues [44], more studies are needed to 
confirm the links between miR-143 and K-Ras, Bcl-2, FHIT and DNMT3A in gastric 
cancer. 
For the first time, we have shown that miR-579 and miR-942 are up-regulated in 
gastric cancer cell lines, although statistical significance was only achieved in the 
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overall comparison. MiR-942 was also up-regulated in three of the tumours (T1, T2 
and T4). In contrast, miR-579 was found to be down-regulated in two tumours (T3 
and T4). Until now, none of these two miRs have been found to target any mRNA, 
therefore their biological meaning remains to be determined. 
MiRNA-mediated gene regulation can be achieved either by direct effects on 
translation (initiation block, premature ribosome drop off, or elongation block) or 
indirect effects on translation (deadenylation and degradation of mRNA) [18,19]. One 
of the aims of our study was to find possible microRNAs targeting 3’UTRs of 
adhesion complex molecules’ mRNAs. We hypothesised that if adhesion complex 
molecules’ mRNAs are direct targets of the studied microRNAs, then an inverse 
relationship should be found between them. We have described some inverse relations 
between all microRNAs and predicted and non-predicted mRNAs, in both gastric 
cancer cell lines and tumours. These findings support the possibility that the studied 
microRNAs can target E-cadherin, α-catenin, β-catenin or p120 mRNAs and 
consequently disrupt adhesion complex. However, we have found no significant 
Spearman’s correlation (only a possible inverse correlation between miR-9 and 
CTNNB1 mRNA). This can be explained because direct effects on translation are 
more important than mRNA degradation for microRNA gene regulation [18,19]. 
In conclusion, we reported that miR-9, miR-143, miR-579 and miR-942 are 
differentially expressed in gastric cancer. Our findings were not always concordant 
between cell lines and tumours and even among tumours, reflecting possible different 
roles of miRs in different stages of carcinogenesis. Furthermore, our results may 
predict a possible role for these miRs in the regulation of expression of adhesion 
complex molecules. However, as our expression analysis was unable to establish clear 
relationships, further studies, such as western-blot analysis and luciferase reporter 
assays, should be conducted to clarify our findings. Finally, a possible link between 
miR-143 (which targets DNMT3A [31]) and miR-9 in gastric cancer might be worth 
studying, since promoter methylation has been described as a mechanism responsible 
for miR-9 down-regulation. 
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Figure legends 
Figure 1. Adhesion complex molecules’ mRNAs expression in gastric cancer cell 
lines and tumours. In general, adhesion complex molecules’ mRNAs levels (A – D) 
are down-regulated in gastric cancer cell lines when compared to normal stomach 
(Stm); while in primary tumours the opposite is observed (E). In cell lines, expression 
levels of adhesion complex molecules’ mRNAs are relative to GAPDH (endogenous 
control) and compared to commercial stomach (Stm; dotted line refers to Stm 
expression level for easier visual comparison with cell lines). Error bars represent 
standard error mean (S.E.M.). In tumours, bars represent expression levels relative to 
18S and error bars represent standard error (S.E.). Log10 scale is used in Y axis in 
panel E. T-test was used to compare expression levels of cell lines or tumours with 
normal samples (Stm or pool Stm). * Statistical significance was considered if p < 
0.05. # A different real-time probe (CDH1 1/2) was used to measure and compare 
CDH1 mRNA levels in MKN45 and commercial stomach. 
Figure 2. Expression profile of miR-9 in gastric cancer cell lines and tumours. 
MiR-9 is shown to be down-regulated in gastric cancer cell lines, except in MKN45 
and NCI-N87 (A). However, overall difference of miR-9 between cell lines and 
normal stomach (Stm) was not significant (B). Down-regulation of miR-9 was also 
observed in tumours both individually (C) and collectively (D). Line y = 100 
represents baseline miR-9 expression in commercial stomach (Stm) or stomach pool 
of normal samples (pool Stm). Data is expressed as fold change of miR-9 levels 
normalized to reference sample ± S.E.M. (in gastric cancer cell lines) or S.E. (in 
tumours). Log10 scale is used in Y axis. T-test was used to compare miR-9 to normal 
samples (Stm or pool Stm). * p < 0.05 
Figure 3. Expression profile of miR-143 in gastric cancer cell lines and tumours. 
MiR-143 was significantly under-expressed in all gastric cancer cell lines, both 
individually (A) and collectively (B).  In tumours, T1 revealed down-regulation while 
T2 and T3 revealed up-regulation of miR-143 (C). Overall, no differences exist 
between tumours and normal stomach samples (D). Line y = 100 represents baseline 
miR-143 expression in commercial stomach (Stm) or stomach pool of normal samples 
(pool Stm). Data is expressed as fold change of miR-143 levels normalized to 
reference sample ± S.E.M. (in gastric cancer cell lines) or S.E. (in tumours). Log10 
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scale is used in Y axis. T-test was used to compare miR-143 to normal samples (Stm 
or pool Stm). * p < 0.05 
Figure 4. Expression profile of miR-579 in gastric cancer cell lines and tumours. 
MiR-579 appears to be up-regulated in gastric cancer cell lines (A), although 
statistically significance was only achieved in GP202 (A) and overall comparison (B). 
In contrast, miR-579 expression was significantly down-regulated in T3 and T4 (C). 
Overall comparison did not reveal differences between tumours and normal stomach 
(D). Line y = 100 represents baseline miR-579 expression in commercial stomach 
(Stm) or stomach pool of normal samples (pool Stm). Data is expressed as fold 
change of miR-579 levels normalized to reference sample ± S.E.M. (in gastric cancer 
cell lines) or S.E. (in tumours). Log10 scale is used in Y axis. T-test was used to 
compare miR-579 to normal samples (Stm or pool Stm). * p < 0.05 
Figure 5. Expression profile in miR-942 in gastric cancer cell lines and tumours. 
MiR-942 seems to be up-regulated in gastric cancer cell lines (A), even though 
statistical significance was only achieved in overall comparison (B). Similarly, T1, T2 
and T4 showed significant up-regulation of miR-942 (C). However, T3 revealed 
significant under-expression of miR-942 (C). Overall expression of miR-942 in 
tumours did not appear to be different from normal samples (D). Line y = 100 
represents baseline miR-942 expression in commercial stomach (Stm) or stomach 
pool of normal samples (pool Stm). Data is expressed as fold change of miR-942 
levels normalized to reference sample ± S.E.M. (in gastric cancer cell lines) or S.E. 
(in tumours). Log10 scale is used in Y axis. T-test was used to compare miR-942 to 
normal samples (Stm or pool Stm). * p < 0.05 
Figure 6. Expression relationship between predicted and non-predicted 
miR/mRNA pairs in cell lines. In gastric cancer cell lines, possible relationships 
between microRNAs and adhesion complex molecules’ mRNAs were investigated by 
analysing relationship changes between them, using as a reference the relationship in 
normal stomach (Stm). We found that the relationship between miR-143 and mRNAs 
was inverted in gastric cancer cell lines, except in SNU1 between miR-143/CDH1 
mRNA (B). In addition: SNU1 revealed inversion of the relationship between miR-
9/CDH1 mRNA (A); miR-9 expression was higher than all adhesion complex 
molecules’ mRNAs in MNK45 (A); and SNU1 and AGS cell lines showed inversion 
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of the relationship between miR-579/CDH1 mRNA (C) and miR-942/CDH1 mRNA 
(D). Bars represent expression levels of miRs and mRNAs relative to endogenous 
control ± S.E.M. Cell lines are displayed by increasing levels of miR. Dotted lines 
represent miR expression in normal stomach. Log10 scale is used in Y axis. 
Figure 7. Expression relationship between predicted and non-predicted 
miR/mRNA pairs in tumours. In tumours, possible relationships between 
microRNAs and adhesion complex molecules’ mRNAs were investigated by 
analysing relationship changes between them, using as a reference the relationship in 
normal stomach (pool Stm). The relationship between miR-9 and all adhesion 
complex molecules’ mRNAs was shifted, expect for CTNND1 in all tumours and 
miR-9/CDH1 mRNA in tumour T1 (A). In tumours T3 and T4, the relationship 
between miR-579 and all adhesion complex molecules’ mRNAs was inverted (C). 
MiR-942 shifted its relationship with CDH1, CTNNA1 and CTNNB1 mRNAs in 
tumour T3, while in tumour T4 only miR-942/CDH1 relationship was inverted (D). 
Concerning miR-143, all tumours maintained their relationship with all adhesion 
complex mRNAs as the normal counterpart (B). Bars represent expression levels of 
miRs and mRNAs relative to endogenous control ± S.E. Tumours are displayed by 
increasing levels of miR. Dotted lines represent miR expression in normal stomach. 
Log10 scale is used in Y axis. 
Figure 8. Correlations between miR/mRNA pairs in gastric cancer cell lines. We 
have not found any significant correlation between miR-9 (A), miR-143 (B), miR-579 
(C), miR-942 (D) and predicted or non-predicted adhesion complex molecules’ 
mRNAs. Dots represent each cell line’s expression levels of miR and mRNA, relative 
to endogenous control (GAPDH and RNU48). Spearman’s correlation was used to 
estimate degree of correlation between miR/mRNA pairs. Statistical significance was 
considered if p < 0.05. 
Figure 9. Correlations between miR/mRNA pairs in tumours. In tumours we 
found a possible (not statistically significant) inverse correlation between miR-9 and 
CTNNB1 (A; p = 0.0833). We have not found any other correlation between studied 
miRs and mRNAs (A – D). Dots represent each tumour’s expression levels of miR 
and mRNA, relative to endogenous control (18S and RNU48). Spearman’s correlation 
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was used to determine degree of correlation between miR/mRNA pairs. Statistical 
significance was considered if p < 0.05. 
Tables 
Table 1. Bioinformatics prediction of microRNA/mRNA pairs. 
miR-9 miR-143 miR-579 miR-942 
CDH1 CDH1 CTNNA1 CTNNA1 
CTNNA1 CTNND1 CTNNB1 CTNND1 
  CTNND1  
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many Academic Editors as you like, but note that we cannot guarantee that they will be used.
Electronic Formats
Our publication system supports a limited range of formats for text and graphics. Text files can be
submitted in only the following formats: Word, LaTeX, and RTF. Graphics files can only be submitted
in the following formats: EPS or TIFF.
If you experience difficulties with the manuscript submission Web site or are concerned about the
suitability of your files, please contact the journal (plosone [at] plos.org).
Prior Publication
When submitting their article, all authors are asked to indicate that they have not submitted a
related or duplicate manuscript for publication elsewhere. If similar or related work has been
submitted elsewhere, then a copy must be included with the article submitted to PLoS. Reviewers
will be asked to comment on the overlap between related submissions.
Financial Disclosure
This section should describe sources of funding that have supported the work. Please include
relevant grant numbers and the URL of any funder's Web site. Please also include this sentence:
"The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript." If this statement is not correct, you must describe the role of any
sponsors or funders, and amend the aforementioned sentence as needed.
Author Status
The involvement of any professional medical writer in publication must be declared. We encourage
authors to consult the European Medical Writers' Association Guidelines on the role of medical
writers. For all PLoS journals, the corresponding author must submit the manuscript, related files,
and all required data and information. From the point of submission through to publication, all
communication related to that manuscript will be directed to and received from the corresponding
author only.
PLoS ONE bases its criteria for authorship on those outlined in the Uniform Requirements for
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Manuscripts Submitted to Biomedical Journals, which are summarized below. The contributions of
all authors must be described. Contributions that fall short of authorship should be mentioned in the
acknowledgements.
"Authorship credit should be based on
Authors should meet conditions 1, 2, and 3.
When a large, multi-center group has conducted the work, the group should identify the
individuals who accept direct responsibility for the manuscript (3). These individuals should
fully meet the criteria for authorship defined above and editors will ask these individuals to
complete journal-specific author and competing interests disclosure forms. When submitting a
group author manuscript, the corresponding author should clearly indicate the preferred
citation and should clearly identify all individual authors as well as the group name.
Acquisition of funding, collection of data, or general supervision of the research group, alone,
does not justify authorship. All persons designated as authors should qualify for authorship,
and all those who qualify should be listed. Each author should have participated sufficiently in
the work to take public responsibility for appropriate portions of the content."
PLoS journals follow the COPE guidelines covering changes in authorship. Please note that if any
changes to the list of authors of a manuscript are necessary after the initial submission of a
manuscript to a PLoS journal but before its publication, the corresponding author must first contact
the journal staff and provide a clear reason for the change(s). If the change to the authorship list is
appropriate and in keeping with the guidelines above, the corresponding author will be asked to
provide written confirmation that all other authors listed on the manuscript at that time consent to
the change(s). Any individuals who the corresponding author requests to add or remove from the
list of authors will be contacted.
Competing Interests
The submitting author is asked at submission to declare, on behalf of all authors, whether there are
any financial, personal, or professional interests that could be construed to have influenced the
paper. Reviewers are also asked to declare any interests that might interfere with their objective
assessment of a manuscript. Any relevant competing interests of authors must be available to
editors and reviewers during the review process and will be stated in published articles. Read more
about the policy of PLoS regarding competing interests.
Abbreviations
Please keep abbreviations to a minimum and define them upon first use in the text. Non-standard
abbreviations should not be used unless they appear at least three times in the text.
Figures
For the article to be accepted for publication, the author will need to supply high-resolution versions
of the figures. When preparing your figures, please ensure that the files conform to our Guidelines
for Figure and Table Preparation. Please do not upload panels for a single figure separately (for
example, Figure 1A, Figure 1B-1D, Figure 1E); each figure file should be a single montage of all
panels.
substantial contribution to conception and design, or acquisition of data, or analysis and interpretation of
data;
1.
drafting the article or revising it critically for important intellectual content; and2.
final approval of the version to be published.3.
http://www.plosone.org/static/guidelines.action
6 de 20
Please note that PLoS ONE can only accept figures submitted as either TIFF or EPS files.
PLoS does not accept vector EPS figures generated using LaTeX. We only accept LaTeX generated
figures in TIFF format. Export your LaTeX files as PDFs, and then open them in GIMP or Photoshop
and save as TIFF. In general, Figures must be generated in a standalone graphics application such
as Adobe Illustrator, InkScape, PyMol, MatLab, SAS, etc. Please see our Figure Guidelines for more
information.
All figures will be published under a Creative Commons Attribution License, which allows them to be
freely used, distributed, and built upon as long as proper attribution is given. Please do not submit
any figures that have been previously copyrighted unless you have express written permission from
the copyright holder to publish under the CCAL license.
When using our Submission software, you will have an opportunity to review your image quality via
automated checks. This 2 minute Video Short explains how to use this feature.
Microsoft Word Files
Articles can be submitted for review in DOC, DOCX, RTF, or PDF. Any articles that have been
prepared in LaTeX will be accepted for review, but only in PDF format. After acceptance, only text
files (RTF or DOC) of the revised manuscript and tables can be accepted for use in the production
process.
Math Equations and DOCX
If your manuscript is or will be in DOCX and contains equations, you must follow the instructions
below to make sure that your equations are editable when the file enters production.
If you have not yet composed your article, you can ensure that the equations in your DOCX file
remain editable in DOC by enabling “Compatibility Mode” before you begin. To do this, open a new
document and save as Word 97-2003 (*.doc). Several features of Word 2007/10 will now be
inactive, including the built-in equation editing tool. You can insert equations in one of the two
ways listed below.
If you have already composed your article as DOCX and used its built-in equation editing tool, your
equations will become images when the file is saved down to DOC. To resolve this problem, re-key
your equations in one of the two following ways.
If, when saving your final document, you see a message saying “Equations will be converted to
images,” your equations are no longer editable and PLoS will not be able to accept your file.
Organization of the Manuscript
Most articles published in PLoS ONE are organized in one of four fashions:
Title, Authors, Affiliations, Abstract, Introduction, Results, Discussion, Materials and Methods,
Acknowledgments, References, Figure Legends, and Tables.
Title, Authors, Affiliations, Abstract, Introduction, Methods, Results, Discussion, Acknowledgments,
References, Figure Legends, and Tables.
Title, Authors, Affiliations, Abstract, Introduction, Analysis, Discussion, Acknowledgments,
References, Figure Legends, and Tables.
Title, Authors, Affiliations, Abstract, Introduction, Results, Design and Implementation, Availability
and Future Directions, Acknowledgments, References, Figure Legends, and Tables. [NB This template
applies most centrally to those manuscripts where new software forms a central part of the
Use MathType to create the equation. MathType is the recommended method for creating equations.1.
Go to Insert > Object > Microsoft Equation 3.0 and create the equation.2.
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submission.]
We advise that abstracts should not exceed 250–300 words. There are no specific length restrictions
for the remaining sections of the manuscript; however, we urge authors to present and discuss their
findings concisely.
You should include continuous line numbering throughout your manuscript.
Standard Microsoft Word templates are available to help authors prepare their manuscripts. The
templates consist of a standard set of headings that make up research articles of various types, with
guidance regarding what to include in each section.
Download templates:
Standard Research article
Clinical Research article
Systematic Review / Meta-Analysis article
Clinical Trial article
Research Article Describing New Software
If you would like to submit your manuscript using LaTeX, you must author your article using the
PLoS ONE LaTeX template. Articles prepared in LaTeX may be submitted in PDF format for use
during the review process. After acceptance, however, .tex files and formatting information will be
required as a zipped file. Please consult our LaTeX guidelines for a list of what will be required.
Title (150 characters or fewer)
The title should be specific to the project, yet concise. It should be comprehensible to readers
outside your field. Avoid specialist abbreviations, if possible. Titles should be presented in title case,
meaning that all words except for prepositions, articles, and conjunctions should be capitalized.
Where appropriate authors should ensure the title contains information about the species or model
system in which a study has been done (for biological papers) or type of study design (for clinical
papers).
During the online submission process, you will also provide a "short title" of 50 characters or fewer.
Authors and Affiliations
Provide the first names or initials (if used), middle names or initials (if used), surnames, and
affiliations—department, university or organization, city, state/province (if applicable), and
country—for all authors. One of the authors should be designated as the corresponding author. It is
the corresponding author’s responsibility to ensure that the author list, and the summary of the
author contributions to the study are accurate and complete. If the article has been submitted on
behalf of a consortium, all author names and affiliations should be listed at the end of the article.
Abstract
The abstract succinctly introduces the paper and should not exceed 300 words. It should mention
the techniques used without going into methodological detail and should summarize the most
important results. Please do not include any citations in the abstract. Avoid specialist abbreviations
if possible.
Examples:
Impact of Cigarette Smoke Exposure on Innate Immunity: A Caenorhabditis elegans Model
Solar Drinking Water Disinfection (SODIS) to Reduce Childhood Diarrhoea in Rural Bolivia: A Cluster-
Randomized, Controlled Trial
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Registration
Registration details should be included when reporting results of a clinical trial (see "Reporting
Clinical Trials" for details). For each location that your trial is registered, please list: name of
registry, registry number, and URL of your trial in the registry database.
Introduction
The introduction should put the focus of the manuscript into a broader context. As you compose the
introduction, think of readers who are not experts in this field. Include a brief review of the key
literature. If there are relevant controversies or disagreements in the field, they should be
mentioned so that a non-expert reader can delve into these issues further. The introduction should
conclude with a brief statement of the overall aim of the experiments and a comment about
whether that aim was achieved.
Results
The results section should provide details of all of the experiments that are required to support the
conclusions of the paper. There is no specific word limit for this section. The section may be divided
into subsections, each with a concise subheading. Large datasets, including raw data, should be
submitted as supporting information files; these are published online alongside the accepted article.
We advise that the results section be written in past tense.
Discussion
The discussion should spell out the major conclusions of the work along with some explanation or
speculation on the significance of these conclusions. How do the conclusions affect the existing
assumptions and models in the field? How can future research build on these observations? What
are the key experiments that must be done? The discussion should be concise and tightly argued.
Conclusions firmly established by the presented data, hypotheses supported by the presented data,
and speculations suggested by the presented data should be clearly identified as such. The results
and discussion may be combined into one section, if desired.
Materials and Methods
This section should provide enough detail to allow full replication of the study by suitably skilled
investigators. Protocols for new methods should be included, but well-established protocols may
simply be referenced. We encourage authors to submit, as separate supporting information files,
detailed protocols for newer or less well-established methods. These are published online only, but
are linked to the article and are fully searchable.
Acknowledgments
People who contributed to the work but do not fit the criteria for authors should be listed in the
Acknowledgments, along with their contributions. You must also ensure that anyone named in the
Acknowledgments agrees to being so named.
Details of the funding sources that have supported the work should be confined to the funding
statement provided in the online submission system. Do not include them in the acknowledgments.
References
Only published or accepted manuscripts should be included in the reference list. Meetings abstracts,
conference talks, or papers that have been submitted but not yet accepted should not be cited.
Limited citation of unpublished work should be included in the body of the text only. All personal
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communications should be supported by a letter from the relevant authors.
Download EndNote output style file for EndNote 8 and above or EndNote 4-7 (right-click the link to
download the file to your computer)
Download BibTeX style file (right-click the link to download the file to your computer)
PLoS uses the numbered citation (citation-sequence) method. References are listed and numbered
in the order that they appear in the text. In the text, citations should be indicated by the reference
number in brackets. Multiple citations within a single set of brackets should be separated by
commas. Where there are three or more sequential citations, they should be given as a range.
Example: "... has been shown previously [1,4-6,22]." Make sure the parts of the manuscript are in
the correct order before ordering the citations.
Because all references will be linked electronically as much as possible to the papers they cite,
proper formatting of the references is crucial. Please use the following style for the reference list:
Published Papers
1. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc
Natl Acad Sci U S A 74: 5463-5467.
Please list the first five authors and then add "et al." if there are additional authors. Use of a DOI
number to the full-text article is acceptable as an alternative to or in addition to traditional volume
and page numbers.
Accepted Papers
Same as above, but "in press" appears instead of the page numbers. Example: Adv Clin Path. In
press.
Electronic Journal Articles 1. Loker WM (1996) "Campesinos" and the crisis of modernization in Latin
America. Jour Pol Ecol 3. Available: http://www.library.arizona.edu/ej/jpe/volume_3/ascii-
lokeriso.txt. Accessed 2006 Aug 11.
Books
1. Bates B (1992) Bargaining for life: A social history of tuberculosis. Philadelphia: University of
Pennsylvania Press. 435 p.
Book Chapters
1. Hansen B (1991) New York City epidemics and history for the public. In: Harden VA, Risse GB,
editors. AIDS and the historian. Bethesda: National Institute of Health. pp. 21-28.
Figure Legends
The aim of the figure legend should be to describe the key messages of the figure, but the figure
should also be discussed in the text. An enlarged version of the figure and its full legend will often
be viewed in a separate window online, and it should be possible for a reader to understand the
figure without switching back and forth between this window and the relevant parts of the text.
Each legend should have a concise title of no more than 15 words. The legend itself should be
succinct, while still explaining all symbols and abbreviations. Avoid lengthy descriptions of methods.
Tables
Tables should be included in the text file, at the very end of the manuscript. All tables should have
a concise title. Footnotes can be used to explain abbreviations. Citations should be indicated using
the same style as outlined above. Tables occupying more than one printed page should be avoided,
if possible. Larger tables can be published as online supporting information. Please ensure that table
formatting conforms to our Guidelines for Figure and Table Preparation.
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1. Introduction
As part of the process of making scientific and medical literature openly accessible on the Web,
PLoS uses a streamlined production process that takes authors' submitted figures straight to the
formatting stage. Most importantly, PLoS does not redraw figures accepted for publication in
articles. Therefore, figure preparation is the author's responsibility.
Please read the following guidelines carefully and thoroughly. Failure to comply with these
guidelines may result in lower-quality figures and prolonged publishing time of your article.
2. Creative Commons Attribution License
All figures and photographic images will be published under a Creative Commons Attribution License
(CCAL), which allows them to be freely used, distributed, and built upon as long as proper
attribution is given. Please do not submit any figures or photos that have been previously
copyrighted unless you have express written permission from the copyright holder to publish under
the CCAL license.
For license inquiries, e-mail license [at] plos.org.
3. Titles and Legends
Titles and legends (captions) for main figures (i.e., not Supporting Figures) should be included in
the main article file, not as part of the figure files themselves. Figure legends do not need to be
uploaded to the online system. Do not include author names or the article title within the figure
files. Instead, list the following information for each figure at the end of the article file, after the
references, but before any tables:
Figure number (in sequence, using Arabic numerals: Figure 1, Figure 2, Figure 3, etc.)
Short title using a maximum of 15 words. The figure title should be bold type, using sentence
case ending with a period (.). For example: Figure 1. Adaptation and its potential costs.
A detailed legend of 300 words maximum can follow the figure title. Each panel should be
described in the legend (see Panel Labels, below).
For more detailed information on Legends, see Author Guidelines: Figure Legends
Supporting Figures. If Supporting Information figures are going to be published with your paper,
please include the captions in the article file.
Note: If at any point you have to change the numbering order of your figures, you must make sure
that all figure captions correctly correspond with the figures.
4. General Considerations
There are two broad categories of figures in PLoS articles: (1) those publishing directly with the
Table Guidelines
Borders, Lines, and Rules
Returns
Shading
Footnotes
Vertically Merged Cells
Multi-part Tables
LaTeX Tables
12.
Getting Help13.
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article and (2) Supporting Information figures.
Supporting Figures are not published directly in the article; rather, a hyperlink to the figure is
provided in the online version of the published article. Figures published as Supporting Information
can be in any file format or dimension, as long as they are no larger than 10 MB.
Provide a separate file for every figure in your manuscript, including Supporting Information
figures. Figures should not be embedded in the main manuscript file. For example, if your
manuscript has 10 figures, you would upload 10 individual files. Authors who prepared their articles
using LaTeX should consult the relevant part of these guidelines.
Recommended Graphics Software
Several graphics software packages are available to help you create high-quality graphics:
Adobe Photoshop
Adobe Illustrator
PowerPoint
CorelDraw
GIMP (freely distributed at www.gimp.org)
Inkscape (freely distributed at www.inkscape.org)
Note: Microsoft PowerPoint
PowerPoint is a presentation program, used to display information, normally in the form of a slide
show. While it is not designed to create artwork for publication, there are simple workarounds that
will allow you to submit your PowerPoint figures. Please see the PowerPoint FAQ at the end of these
guidelines.
Note: Microsoft Word
PLoS does not recommend using Microsoft Word to adjust image size. Microsoft Word automatically
down-samples figures and embeds them in the document at 72 ppi, so the images may be at a lower
resolution and quality than is acceptable. We require that figures be created at a minimum
resolution of 300 ppi. Please see the Word FAQ at the end of these guidelines.
Note: Microsoft Excel
PLoS does not recommend Excel to make or adjust figures, except for charts, graphs, or histograms
generated from cell data. It lacks the capability to manipulate figures that dedicated graphics
applications (such as GIMP, Photoshop, or Illustrator) have. Other than creating charts, graphs, or
histograms, Excel should be only be used to make tables. See Table Guidelines for more
information on formatting tables. Please see the Excel FAQ at the end of these guidelines.
Note: Microsoft Paint
Microsoft Paint is incapable of creating files at higher than 96ppi resolution, so PLoS strongly
recommends that you never use it in creating your figures. If you must, follow the guidelines below
under Export from Stata.
Note: LaTeX
PLoS does not accept vector EPS figures generated using LaTeX. We only accept LaTeX generated
figures in TIFF format. Export your LaTeX files as PDFs, and then open them in GIMP and save as
TIFF. In general, Figures must be generated in a standalone graphics application such as those
listed above, or PyMol, MatLab, SAS, etc.
5. Figure Preparation
File Size
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Individual figure files should not exceed 10 MB. If you are having trouble reducing the size of your
files, refer to the section below titled Reduce TIFF File Size with LZW Compression.
Figure Quality
A figure that looks good on screen may not be at optimal resolution. Test your figures by sizing
them to their intended dimensions (see Quick Reference: Dimensions) and then printing them on
your personal printer. The online version should look relatively similar to the personal-printer copy:
it should not look fuzzy, jagged, pixilated, or grainy at the intended print size.
Note: The quality of your figures will be only as good as the lowest-resolution element placed in
them. In other words, if you created a 72 ppi line graph and placed in it a 300 ppi TIFF, it will be
upsampled, resulting in it looking blurred, jagged, or pixelated.
Figure Format
Figures for publication must only be submitted in high-resolution TIFF or EPS format. Some figure
types should be submitted in TIFF only (see Figure Types below). If you have not made any
annotations to your image, and you have a high-quality TIFF, there is no need to submit it
embedded in an EPS, as there will be no increase in quality as a result. See How To: Convert Other
File Types to TIFF below for more information on converting figure files to TIFF.
Color Mode
Figures containing color should be saved in either Grayscale or RGB (millions of colors), rather than
Indexed Color, CMYK or any other color space. Grayscale or RGB files should be saved with a bit
depth of 8 bits per channel, not 16. Bitmap (monochrome) images are not acceptable.
Layered TIFFs
TIFF files with multiple layers are not an accepted format for figures. Please make sure you provide
us with a flattened version of your file. To flatten a layered TIFF file, open your figure in Photoshop.
From the menu bar select Layer/Flatten Image and save the file. See also Combination Figures,
below.
Figure example that has layers. Figure example that has the layers flattened.
Only the Background layer remains.
Multi-Page TIFFS
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TIFF files with multiple pages are not an accepted format for figures.
Background Color
Create your figures using a white background. If you create figures using a transparent background,
the figures may not display well in the online format.
Figure example showing a figure created with a
transparent background. Transparent
backgrounds do not work well in the online
format.
Figure example showing a figure created with a
white background. White backgrounds display
well in any format.
Lines, Rules, and Strokes
Lines should be at least 0.5 point and no more than 1.5 point in order to reproduce well in a PDF
file or web format.
Figure example showing lines that are too thick
and lines that are too light in color. Light color
do not display well when published.
Figure example showing the correct line widths
and darker colored accent lines.
White Space
Each figure should be closely cropped to minimize the amount of white space surrounding it. PLoS
recommends a 2 point white space border around each figure. Cropping figures improves accuracy
when the figure is placed among other elements during production of the final published article.
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Figure example that has too much white space.
Figure example that has the correct amount of
white space.
Text within Figures
Fonts
Figure text must be in Arial font, between 8 and 12 point. Make sure that the visual information is
readable at the size you select.
Figure text that requires a font family other than Arial (math symbols, etc.) must have the font
information embedded in the figure file, or be converted to outlines. See Embed Fonts in EPS Files
and Convert Text to Outlines below for more information.
Panel labels
Multi-panel figures (those with parts A, B, C, and D) should be submitted as a single file that
contains all parts of the figure. Label the figure itself with capital letters, Arial bold font, 12 points.
Any TIFFs with layers must be flattened (see Combination Figures below.)
Figure example that has the incorrect label
format.
Figure example that has the correct label
format.
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Figure example showing the use of the
incorrect font family.
Figure example correctly using the Arial font
family.
6. Figure Dimensions
Figures for publication will be sized to fit 1, 1.5, or 2 columns of the final printable PDF of the
article. Dimensions will also depend on the article type. Please follow the sizing recommendations
below for your original submission to create high-quality, appropriately sized figures. See Figure
Types below for descriptions and recommendations for line drawings, grayscale drawings, halftones,
and combination figures. See below for sizing information.
Figure Alignment
Figures will be left-aligned on the page or column, so please design them accordingly.
Figure Width
Widths depend on article type layout and are listed in the tables below, but must be within the
minimum of 3.27in/8.3cm wide and the maximum of 6.83in/17.35cm wide. Figures can have a
maximum height of 9.19in/23.35 cm. If your figures have labels that are in 8 point type or if your
figures are very detailed, it is recommended that your figure be created so that it will span two
columns. Images will be published in a horizontal orientation, and cannot be rotated 90 degrees to
have a vertical orientation. Please size your figure widths to one of the column sizes listed below.
Article Type
2-column: Research Article, Expert Commentary, Guidelines and Guidance, Learning Forum,
Neglected Diseases, PLoS Medicine Debate, Primer, Review, Symposium.
3-column: Editorial, Education, Essay, Health In Action, Historical and Philosophical Perspectives,
Historical Profiles and Perspectives, Interview, Message from ISCB, Opinion, Perspective, Policy Forum,
Policy Platform, Research In Translation, Special Report, Viewpoint.
Quick Reference – Figure Dimensions for Research Articles and Other 2-Column Article Types
Inches Centimeters Points Picas
Width for 1-Column Figures 3.27 8.3 cm 235.53 19.62 picas
Width for 1.5-Column Figures 4.86 12.35 cm 350.33 29.19 picas
Width for 2-Column Figures 6.83 17.35 cm 492.06 41 picas
Height Maximum for All Figures 9.19 23.35 cm 662.14 55.17 picas
Quick Reference – Figure Dimensions for 3-Column Article Types
Inches Centimeters Points Picas
Width for 1-Column Figures 2.09 5.3 cm 150.48 12.54 picas
Width for 2-Column Figures 4.45 11.3 cm 320.56 26.71 picas
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Width for 3-Column Figures 6.83 17.35 cm 492.06 41 picas
Height Maximum for All Figures 9.19 23.35 cm 662.14 55.17 picas
7. Figure Types
Line Art
Line art has sharp, clean lines and geometrical shapes against a white background. Line art is
typically used for tables, charts, graphs, and gene sequences. You can use a program like Illustrator
to create high-quality line art. A minimum resolution of 300 ppi will maintain the crisp edges of the
lines and shapes.
Format: TIFF or EPS
Minimum Resolution: 300 ppi
Grayscale
Grayscale figures contain varying tones of black and white. They contain no color, so grayscale is
synonymous with "black and white." The gray scale is divided into 256 sections with black at 0 and
white at 255. Software for preparation of grayscale art includes Photoshop.
Format: TIFF or EPS
Minimum Resolution: 300 ppi
Halftones
The best example of a halftone is a photograph, but halftones include any image that uses
continuous shading or blending of colors or grays, such as gels, stains, microarrays, brain scans,
and molecular structures. To prepare and manipulate halftone images, use Photoshop or a
comparable photo-editing program.
Format: TIFF
Minimum Resolution: 300 ppi
Combination Figures
Combination figures contain two or more types of images, for example, a halftone figure containing
text. You should embed the images, group the objects, or flatten the layers, and flatten
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transparencies before saving as TIFF at a minimum of 300 ppi.
Format: TIFF
Minimum Resolution: 300 ppi
Stereograms
Stereograms are figures with two almost identical pictures placed side by side which, when viewed
through special glasses or a stereoscope, produce a three-dimensional image.
If you plan on submitting a stereogram as one of your figures, make sure this is clearly mentioned
in the caption for the figure within the manuscript. Stereograms must be sized so that the centers
of each of these images are 63 mm apart. Make sure that the stereogram figure is at the size you
would like them to display. They will be checked prior to publishing, but this step will ensure your
stereogram will be viewed properly.
Quick Reference Table for Common Figure Types
Line Art Grayscale Halftones
Combination
Figures
Required File
Types
TIFF or EPS TIFF or EPS TIFF TIFF
Required
Resolution
300 ppi 300 ppi 300 ppi 300 ppi
Example
Software for
Preparation
Adobe Illustrator
Adobe Photoshop;
GIMP
Adobe
Photoshop;
GIMP
Adobe Photoshop;
GIMP
8. Uploading Figures to the PLoS Manuscript Submission System
Upload Order
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images will be broken down into tiles and recombined after all the images pieces are written
out. This ensures that memory is but built up in writing large images. If the pieces cannot be
recombined, the individual pieces are written out and reported to the user. However, tiff files
of any size can be recombined and written out with compression. The default dots per inch is
set to 300 dpi and the default size if individual pieces for large images is set to 4 MB and tiff
image without tiling enabled. These default parameters can be changed in the tools -!Options
dialog under the Export as Image.
12. Table Guidelines
Tables submitted for publication should be included at the very end of the article file (.doc,
.rtf, .tex). Supporting Information tables should be submitted as separate files in any of the
following formats (although authors should aim to ensure that the file type is most
appropriate to the information displayed): Word (.doc), Excel (.xls), PDF, PPT, JPG, EPS, or
TIFF.
Title and Footnotes
Each table needs a concise title of no more than one sentence, placed above the table with
the table number (e.g., Table 1). The legend and footnotes should be placed below the table.
Footnotes may be used to explain abbreviations.
Specifications
Tables that do not conform to the following requirements may give unintended results when
published. Problems may include the movement of data (rows or columns), loss of spacing, or
disorganization of headings. Note: Multi-part tables with varying numbers of columns or
multiple footnote sections should be divided and renumbered as separate tables.
In the published version, tables will be formatted in PLoS style. This includes alternate row
shading, content left-aligned in cells, title above the table and legend/footnotes below the
table.
Tables must:
Be cell-based (e.g., created in Word with Tables tool (preferred) or in Excel).
Be editable (i.e., not a graphic object).
Have heading/subheading levels in separate columns.
Be no larger than one printed page (7 in x 9.5 in). Larger tables can be published as online
supporting information. Note: some wide tables may be printed sideways in the PDF.
Tables must not:
Use returns or tabs within a cell.
Have color or shading.
Use lines, rules, or borders.
Contain spaces within cells to align text.
Have vertically merged cells; horizontally merged cells are fine.
Have inserted text boxes or pictures.
Have tables within tables.
Include empty columns, rows, or cells to create spacing.
Include hyperlinked text.
If your submitted table contains any of these elements, they will be returned for
adjustments.
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Problem: Using rules to specify layout.
Incorrectly formatted submission
Incorrectly formatted result
Correctly formatted submission - Notice the use of horizontally merged cells.
Correctly formatted result
Problem: Using returns to create rows.
Incorrectly formatted table
Incorrectly formatted result - Notice that the paragraph returns create new rows.
Correctly formatted table
Correctly formatted table results
http://www.plosone.org/static/figureGuidelines.action
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Problem: Use of shading to convey grouping.
Incorrectly formatted table
Incorrectly formatted result - Notice that the submitted shading pattern is lost.
Problem: Footnotes included in table.
Incorrectly formatted table
Correctly formatted table
Problem: Vertically merged cells.
Incorrectly formatted table
Correctly formatted table
http://www.plosone.org/static/figureGuidelines.action
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Problem: Multi-part table.
Incorrectly formatted table
Solution: Separate into two tables.
Problem: LaTeX Table - Use of "\\" within a cell.
Incorrectly formatted table
Incorrectly formatted result - Notice the Unit cells are on a separate row from the Head cells.
Correctly formatted table - Allows text within a cell to wrap.
Correctly formatted table
13. Getting Help
If you have questions about your figures after reading the guidelines, you can e-mail figures
http://www.plosone.org/static/figureGuidelines.action
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